<DOC>
	<DOCNO>NCT01994629</DOCNO>
	<brief_summary>Evaluate immune response reactogenicity one dose Meningococcal ACWY-cross reactive material ( CRM ) Meningococcal ACWY-tetanus toxoid ( TT ) 12-15 month old healthy toddler .</brief_summary>
	<brief_title>Safety Immunogenicity One Dose Novartis ' Meningococcal ACWY-CRM Vaccine GlaxoSmithKline Biologicals ' Meningococcal ACWY-TT Vaccine Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy child 12 month 15 month old inclusive bear estimate gestational age ≥ 37 week . 2 . Parent ( ) /legal guardian ( ) give write informed consent nature study explain accord local regulatory requirement . 3 . Parents/legal guardian available visit would comply requirement protocol ( e.g. , completion Diary Cards , availability study visit / safety phone call ) . 4 . In good health determine outcome medical history , physical examination clinical judgment investigator . 1 . Previous confirm suspected disease cause N. meningitidis . 2 . Previously expose clinically proven meningococcal disease clinical bacterial meningitis without microbiologic characterization , i.e . possible meningococcal disease . 3 . Previously immunized meningococcal vaccine vaccine contain meningococcal antigen ( ) ( licensed investigational ) . 4 . Received within 90 day prior enrollment expect receive study period investigational nonregistered product ( drug vaccine ) . 5 . Received plan receive vaccine within 14 day 30 day administration study vaccine ( Exceptions : Injectable influenza vaccine could administer 14 day prior study vaccination least 14 day study vaccination ) . 6 . Major congenital defect serious chronic disease . 7 . History anaphylaxis , severe vaccine reaction , allergy vaccine component include diphtheria toxoid ( CRM197 ) tetanus toxoid ( TT ) latex . 8 . Required chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior study vaccination . ( For corticosteroid , mean prednisone , equivalent , ≥ 0.5 mg/kg/day . Inhaled topical steroid allow ) . 9 . Receipt immunoglobulins and/or blood product within six month prior study vaccination administration plan study period . 10 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . 11 . Any bleed disorder consider contraindication intramuscular injection . 12 . Moderate severe acute infection and/or fever ( defined temperature ≥ 38°C ) within 3 day prior enrollment . 13 . Systemic antibiotic treatment within 7 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>meningococcal disease</keyword>
	<keyword>child</keyword>
	<keyword>vaccination</keyword>
</DOC>